rapeseed, peanut, olive, cotton seed and fish oils, alone or in combination with glycerine and/or a wax selected from full and/or partial triglycerides of fatty acids.

22. A pharmaceutical formulation according to Claim 1 intended for intravenous use, wherein the hydrophilic phase is aqueous and has a viscosity of from 2500-7500cp at 20°C.

23. A pharmaceutical formulation according to Claim 1 intended for use as a solid formulation, wherein the hydrophilic phase is gel forming, incorporates the opioid in the gel and forms a matrix incorporating the CCK antagonist and the glyceride derivative.

24. A pharmaceutical formulation according to Claim 1, wherein the hydrophilic phase comprises a pharmacologically and pharmaceutically acceptable polymer or salt thereof selected from proteins such as gelatine, hyaluronic acid, alginic acids or salts thereof such as sodium alginate, carboxymethylcellulose (optionally cross-linked), methyl cellulose, other cellulose derivatives which are water-swellable such as hydroxypropylmethylcellulose and hydroxyethyl-cellulose or other water-swellable polymers such as polyvinyl pyrrolidone (PVP) or water-soluble polymers such as lactose.

25. A pharmaceutical formulation according to Claim 1, wherein the carrier is in the form of an oil-in-water emulsion.

26. A pharmaceutical formulation according to Claim 25, wherein the oil-in-water emulsion comprises

(I) an oil phase comprising a glyceride derivative; and

(ii) an aqueous phase optionally comprising a buffer whereby the emulsion has a pH of from 6.5 to 7.5 and optionally comprises an isotonicty regulator whereby the aqueous phase is made isotonic to blood plasma.

27. A pharmaceutical formulation according to Claim 25, wherein the average particle size of the emulsion is from 0.2 to 3.0μm.

28. A pharmaceutical formulation according to claim 25 further comprising an emulsifying agent, a surfactant and/or a pH adjuster.

29. A pharmaceutical formulation according to Claim 1, wherein the CCK antagonist is incorporated into the organic phase and the opioid is incorporated into the hydrophilic phase.

30. A pharmaceutical formulation according to Claim 1, wherein the ratio of component (i) to component (ii) is within the range of 10:1 to 1:5 by weight.

31. A pharmaceutical formulation according to Claim 1, wherein the ratio of component (a) to component (b) is within the range of 1:2 to 1:40 weight.

32. A pharmaceutical formulation according to Claim 1, wherein the CCK antagonist is selected from the group consisting of 3S-(-)-(1,3-dihydro-3-(2-indolecarbonylamino)-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one;

3R-3-(N-(3-methylphenyl)ureido)-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one;

N-[1,3-dihydro-1-methy-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N-[3-(1,2,4-oxodiazol-5-one)phenyl]urea;

(-)-N-[2,3,-dihydro-5-(4,4-dimethylpiperidin-1-yl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[indan-5-yl]urea; and

[N-[(3R)-5-(3-azabi-cyclo[3.2.2]nonan-3-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)urea].

33. A pharmaceutical formulation according to Claim 1, wherein the opioid is selected from the group consisting of morphine, codeine, or a salt thereof, and 14-hydroxymorphinan opioid analgesics and salts thereof.

34. A pharmaceutical formulation according to Claim 1 in the form of a solid formulation, an injectable emulsion, a suppository or a tablet.

35. A pharmaceutical formulation according to Claim 1 in a unit dosage form suitable for the delivery of 0.5 to 300mg per day of CCK antagonist to a patient in need thereof.

36. A pharmaceutical formulation according to Claim 35 in unit dosage from suitable for oral use or use as a suppository for the delivery of 1 to 100mg per day of CCK antagonist to a patient in need thereof.